Tag #Phase 3 Trial

Why is it challenging to create a norovirus vaccine, and how does Moderna's approach address these challenges?

The accelerated trial enrollment reflects the severity of this winter's norovirus outbreak, which saw a 36% increase in outbreaks by December 11th compared to the previous year. The vaccine targets three common norovirus genotypes, but not the dominant strain in this year's outbreak; success will depend on whether it offers broader protection. This highlights the challenge of developing a universal norovirus vaccine given its rapid mutation rate.